JP2009538276A - 嚢胞性線維症の改良型治療 - Google Patents
嚢胞性線維症の改良型治療 Download PDFInfo
- Publication number
- JP2009538276A JP2009538276A JP2009507606A JP2009507606A JP2009538276A JP 2009538276 A JP2009538276 A JP 2009538276A JP 2009507606 A JP2009507606 A JP 2009507606A JP 2009507606 A JP2009507606 A JP 2009507606A JP 2009538276 A JP2009538276 A JP 2009538276A
- Authority
- JP
- Japan
- Prior art keywords
- deoxynojirimycin
- group
- carbon atoms
- use according
- gba2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000003883 Cystic fibrosis Diseases 0.000 title claims abstract description 44
- 238000011282 treatment Methods 0.000 title claims abstract description 10
- 102100027814 Non-lysosomal glucosylceramidase Human genes 0.000 claims abstract description 43
- 239000003112 inhibitor Substances 0.000 claims abstract description 29
- 101000859679 Homo sapiens Non-lysosomal glucosylceramidase Proteins 0.000 claims abstract description 28
- 239000012528 membrane Substances 0.000 claims abstract description 28
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical class OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 claims abstract description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 230000002209 hydrophobic effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 9
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- -1 [beta] -cholestanol Chemical compound 0.000 claims description 4
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- BGMYHTUCJVZIRP-UHFFFAOYSA-N Nojirimycin Natural products OCC1NC(O)C(O)C(O)C1O BGMYHTUCJVZIRP-UHFFFAOYSA-N 0.000 claims 1
- BGMYHTUCJVZIRP-GASJEMHNSA-N nojirimycin Chemical compound OC[C@H]1NC(O)[C@H](O)[C@@H](O)[C@@H]1O BGMYHTUCJVZIRP-GASJEMHNSA-N 0.000 claims 1
- 101710083785 Non-lysosomal glucosylceramidase Proteins 0.000 abstract description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 14
- 102000004190 Enzymes Human genes 0.000 abstract description 14
- 108090000790 Enzymes Proteins 0.000 abstract description 14
- 230000001225 therapeutic effect Effects 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 10
- 230000035772 mutation Effects 0.000 abstract description 4
- 230000003389 potentiating effect Effects 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract description 2
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 18
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000002919 epithelial cell Anatomy 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- XVYLNHVEAOOEGI-FAIWKWDXSA-N (2r,3r,4r,5s)-1-[5-(1-adamantylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCOCC1(C2)CC(C3)CC2CC3C1 XVYLNHVEAOOEGI-FAIWKWDXSA-N 0.000 description 9
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 description 9
- 108091000114 ceramide glucosyltransferase Proteins 0.000 description 9
- 150000002772 monosaccharides Chemical class 0.000 description 9
- 125000001841 imino group Chemical group [H]N=* 0.000 description 8
- 238000012937 correction Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 229940106189 ceramide Drugs 0.000 description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 150000002339 glycosphingolipids Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 108010017544 Glucosylceramidase Proteins 0.000 description 3
- 102000004547 Glucosylceramidase Human genes 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YUDPTGPSBJVHCN-YMILTQATSA-N 4-methylumbelliferyl beta-D-glucoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-YMILTQATSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100282794 Caenorhabditis elegans gba-2 gene Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 101710106714 Shutoff protein Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 101150073411 gba-2 gene Proteins 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 2
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229940123455 Beta glucosidase inhibitor Drugs 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000012571 GlutaMAX medium Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-YIDFTEPTSA-N IDOSE Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-YIDFTEPTSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002305 glucosylceramides Chemical class 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 229960001512 miglustat Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79408806P | 2006-04-24 | 2006-04-24 | |
| PCT/NL2007/050177 WO2007123403A1 (en) | 2006-04-24 | 2007-04-24 | Improved treatment of cystic fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009538276A true JP2009538276A (ja) | 2009-11-05 |
| JP2009538276A5 JP2009538276A5 (enExample) | 2010-04-08 |
Family
ID=38283020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507606A Ceased JP2009538276A (ja) | 2006-04-24 | 2007-04-24 | 嚢胞性線維症の改良型治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8410081B2 (enExample) |
| EP (1) | EP2010551B1 (enExample) |
| JP (1) | JP2009538276A (enExample) |
| CN (1) | CN101479288B (enExample) |
| AT (1) | ATE479696T1 (enExample) |
| AU (1) | AU2007241622A1 (enExample) |
| BR (1) | BRPI0710883A2 (enExample) |
| CA (1) | CA2650311A1 (enExample) |
| DE (1) | DE602007008870D1 (enExample) |
| WO (1) | WO2007123403A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| JP5600329B2 (ja) | 2009-02-23 | 2014-10-01 | ユナイテッド セラピューティクス コーポレーション | イミノ糖およびウイルス性疾患を治療する方法 |
| KR101787434B1 (ko) * | 2009-02-24 | 2017-11-15 | 유나이티드 세러퓨틱스 코오포레이션 | 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법 |
| JP5634510B2 (ja) | 2009-06-12 | 2014-12-03 | ユナイテッド セラピューティクス コーポレイション | イミノ糖ならびにブニヤウイルスおよびトガウイルス疾患を治療する方法 |
| KR101459530B1 (ko) * | 2009-09-04 | 2014-11-07 | 유나이티드 세러퓨틱스 코오포레이션 | 폭스바이러스 감염의 치료 방법 |
| KR101497194B1 (ko) * | 2009-09-04 | 2015-02-27 | 유나이티드 세러퓨틱스 코오포레이션 | 오르토믹소바이러스 감염의 치료 방법 |
| JP5752689B2 (ja) * | 2009-09-04 | 2015-07-22 | ユナイテッド セラピューティクス コーポレイション | フィロウイルス疾患を治療するイミノ糖および方法 |
| GB201000499D0 (en) | 2010-01-13 | 2010-03-03 | Fleet George W J | Treatment of cystic fibrosis |
| WO2011095772A2 (en) | 2010-02-04 | 2011-08-11 | Summit Corporation Plc | Novel iminosugar therapeutics |
| GB201006434D0 (en) | 2010-04-19 | 2010-06-02 | Summit Corp Plc | Novel iminosugar combinations |
| EP3741384A1 (en) | 2011-09-07 | 2020-11-25 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
| CN109529028A (zh) | 2012-06-01 | 2019-03-29 | 西奈山伊坎医学院 | 在感染的治疗和预防中的神经酰胺水平 |
| US20150346185A1 (en) * | 2012-12-05 | 2015-12-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Diagnosis of cystic fibrosis |
| WO2014160390A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
| WO2017178499A1 (en) | 2016-04-11 | 2017-10-19 | Spedding Research Solutions | Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units |
| RS67675B1 (sr) | 2017-06-01 | 2026-02-27 | Idorsia Pharmaceuticals Ltd | Kristalni oblik n‐butildeoksigalaktonojirimicina |
| BR112023018404A2 (pt) * | 2021-03-12 | 2023-11-28 | Excepgen Inc | Sistemas e métodos para expressão de proteína |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040118A1 (en) * | 2003-10-29 | 2005-05-06 | Macrozyme B.V. | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| WO2005046672A2 (fr) * | 2003-11-07 | 2005-05-26 | Centre National De La Recherche Scientifique | Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998002161A1 (en) | 1996-07-15 | 1998-01-22 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| AU5799500A (en) * | 1999-06-29 | 2001-01-22 | Mcgill University | Human alpha 1,2-mannosidase |
| WO2005123055A2 (en) * | 2004-06-14 | 2005-12-29 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
| CA2616537A1 (en) | 2005-07-27 | 2007-02-01 | University Of Florida Research Foundation, Inc. | Small compounds that correct protein misfolding and uses thereof |
-
2007
- 2007-04-24 AU AU2007241622A patent/AU2007241622A1/en not_active Abandoned
- 2007-04-24 CA CA002650311A patent/CA2650311A1/en not_active Abandoned
- 2007-04-24 JP JP2009507606A patent/JP2009538276A/ja not_active Ceased
- 2007-04-24 EP EP07747401A patent/EP2010551B1/en not_active Not-in-force
- 2007-04-24 AT AT07747401T patent/ATE479696T1/de not_active IP Right Cessation
- 2007-04-24 US US12/298,506 patent/US8410081B2/en not_active Expired - Fee Related
- 2007-04-24 CN CN2007800237886A patent/CN101479288B/zh not_active Expired - Fee Related
- 2007-04-24 BR BRPI0710883-4A patent/BRPI0710883A2/pt not_active IP Right Cessation
- 2007-04-24 WO PCT/NL2007/050177 patent/WO2007123403A1/en not_active Ceased
- 2007-04-24 DE DE602007008870T patent/DE602007008870D1/de active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040118A1 (en) * | 2003-10-29 | 2005-05-06 | Macrozyme B.V. | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| WO2005046672A2 (fr) * | 2003-11-07 | 2005-05-26 | Centre National De La Recherche Scientifique | Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
Non-Patent Citations (1)
| Title |
|---|
| JPN6012044955; ＦＥＢＳ Ｌｅｔｔｅｒｓ Ｖｏｌ．５８０, 200603, ｐｐ．２０８１-６ * |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE479696T1 (de) | 2010-09-15 |
| WO2007123403A1 (en) | 2007-11-01 |
| CN101479288B (zh) | 2012-06-27 |
| BRPI0710883A2 (pt) | 2011-08-09 |
| CN101479288A (zh) | 2009-07-08 |
| CA2650311A1 (en) | 2007-11-01 |
| US8410081B2 (en) | 2013-04-02 |
| AU2007241622A1 (en) | 2007-11-01 |
| DE602007008870D1 (de) | 2010-10-14 |
| EP2010551B1 (en) | 2010-09-01 |
| AU2007241622A8 (en) | 2008-12-04 |
| EP2010551A1 (en) | 2009-01-07 |
| US20090186862A1 (en) | 2009-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101479288B (zh) | 囊性纤维化的改进的治疗 | |
| US20240398729A1 (en) | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | |
| ES2144980T3 (es) | Composiciones para tratar la rinitis alergica y otros trastornos descarboetoxiloratadina. | |
| US9034847B2 (en) | Inhibiting inflammation with milk oligosaccharides | |
| US20020115619A1 (en) | Compositions and methods for treatment of cystic fibrosis | |
| US20240058353A1 (en) | Methods for treating gi tract disorders | |
| KR20160037169A (ko) | 레트 증후군 및 그를 위한 치료 | |
| US20250049813A1 (en) | Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis | |
| US6656912B2 (en) | Methods to treat α1-antitrypsin deficiency | |
| PT1033979E (pt) | Combinação de inibidores da enzima cyp2a e nicotina e sua utilização terapêutica | |
| AU2011208939B2 (en) | Compounds for use in the treatment of diseases | |
| WO2020261230A1 (en) | Combination therapy with acetyl-leucine and miglustat | |
| KR20060025607A (ko) | 염증성 장 질환의 예방 및(또는) 치료제 | |
| JP5339708B2 (ja) | システイン類を有効成分とするマトリックスメタロプロテアーゼ−８阻害剤及び糖尿病患者又は耐糖能障害を有する者用の歯周病予防又は治療組成物 | |
| EP4640223A1 (en) | Pharmaceutical composition for prevention or treatment of cardiovascular disease, comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker | |
| TW202410903A (zh) | 治療肌肉萎縮性脊髓側索硬化症之方法及組成物 | |
| JPH0466538A (ja) | 抗潰瘍剤 | |
| JPH0672884A (ja) | α‐アミラーゼ阻害剤及びそれを用いた医薬 | |
| TW202539666A (zh) | Gm1神經節苷脂儲積症之治療 | |
| KR20240001620A (ko) | hsa-miR-4517 발현 촉진제를 포함하는 천식 예방, 치료, 또는 개선용 조성물 및 마이크로코커스 루테우스 유래 소포를 이용한 천식 진단방법 | |
| JPH07188033A (ja) | エンドセリン変換酵素阻害剤 | |
| Rajakulasingam et al. | The temporal relationship between the neural and vascular actions of kallidin within the nose | |
| PAXTON | and MICHAEL DRAGUNOW, Ph. D. | |
| MX2007014396A (es) | Composicion farmaceutica que comprende 1-(3-clorofenil)-3- alquilpiperazina para el tratamiento de trastorno alimenticio. | |
| HK1216848B (en) | Methods for treating gi tract disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120828 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121129 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130321 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130730 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20131122 |